The Phase 1 trial for ACE-031 is pending.
October 20, 2008 - Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced the initiation of a Phase 1 clinical study of ACE-031, its lead compound...